The genetic basis of myelodysplastic syndromes (MDS) is heterogeneous, and various combinations of somatic mutations are associated with different clinical phenotypes and outcomes. Whether the genetic basis of MDS influences the outcome of allogeneic hematopoietic stem-cell transplantation (HSCT) is unclear.
Della Porta, M., Galli, A., Bacigalupo, A., Zibellini, S., Bernardi, M., Rizzo, E., et al. (2016). Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation. JOURNAL OF CLINICAL ONCOLOGY, 34(30), 3627-3637 [10.1200/JCO.2016.67.3616].
Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation
VOSO, MARIA TERESA;
2016-01-01
Abstract
The genetic basis of myelodysplastic syndromes (MDS) is heterogeneous, and various combinations of somatic mutations are associated with different clinical phenotypes and outcomes. Whether the genetic basis of MDS influences the outcome of allogeneic hematopoietic stem-cell transplantation (HSCT) is unclear.| File | Dimensione | Formato | |
|---|---|---|---|
|
Della Porta Jco 2016.pdf
accesso aperto
Licenza:
Copyright dell'editore
Dimensione
1.02 MB
Formato
Adobe PDF
|
1.02 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
